Richard A Klinghoffer
Overview
Explore the profile of Richard A Klinghoffer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
730
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gundle K, Rajasekaran K, Houlton J, Deutsch G, Ow T, Maki R, et al.
Front Pharmacol
. 2024 Apr;
15:1367581.
PMID: 38681192
Drug development is systemically inefficient. Research and development costs for novel therapeutics average hundreds of millions to billions of dollars, with the overall likelihood of approval estimated to be as...
2.
Derry J, Burns C, Frazier J, Beirne E, Grenley M, DuFort C, et al.
Clin Cancer Res
. 2023 Jun;
29(18):3813-3825.
PMID: 37389981
Purpose: Cancer drug development is currently limited by a paradigm of preclinical evaluation that does not adequately recapitulate the complexity of the intact human tumor microenvironment (TME). To overcome this,...
3.
Lightcap E, Yu P, Grossman S, Song K, Khattar M, Xega K, et al.
Sci Transl Med
. 2021 Sep;
13(611):eaba7791.
PMID: 34524860
SUMOylation, the covalent conjugation of small ubiquitin-like modifier (SUMO) proteins to protein substrates, has been reported to suppress type I interferon (IFN1) responses. TAK-981, a selective small-molecule inhibitor of SUMOylation,...
4.
Gundle K, Deutsch G, Goodman H, Pollack S, Thompson M, Davis J, et al.
Clin Cancer Res
. 2020 Apr;
26(15):3958-3968.
PMID: 32299817
Purpose: A persistent issue in cancer drug development is the discordance between robust antitumor drug activity observed in laboratory models and the limited benefit frequently observed when patients are treated...
5.
Morris S, Mhyre A, Carmack S, Myers C, Burns C, Ye W, et al.
Oncogene
. 2018 May;
37(31):4226-4238.
PMID: 29717260
While advances in laboratory automation has dramatically increased throughout of compound screening efforts, development of robust cell-based assays in relevant disease models remain resource-intensive and time-consuming, presenting a bottleneck to...
6.
Dey J, Deckwerth T, Kerwin W, Casalini J, Merrell A, Grenley M, et al.
Sci Rep
. 2017 Dec;
7(1):18007.
PMID: 29269870
Aberrant regulation of BCL-2 family members enables evasion of apoptosis and tumor resistance to chemotherapy. BCL-2 and functionally redundant counterpart, MCL-1, are frequently over-expressed in high-risk diffuse large B-cell lymphoma...
7.
Frazier J, Bertout J, Kerwin W, Moreno-Gonzalez A, Casalini J, Grenley M, et al.
Cancer Res
. 2017 Apr;
77(11):2869-2880.
PMID: 28364003
The vision of a precision medicine-guided approach to novel cancer drug development is challenged by high intratumor heterogeneity and interpatient diversity. This complexity is rarely modeled accurately during preclinical drug...
8.
Dey J, Kerwin W, Grenley M, Casalini J, Tretyak I, Ditzler S, et al.
PLoS One
. 2016 Jul;
11(6):e0158617.
PMID: 27359113
While advances in high-throughput screening have resulted in increased ability to identify synergistic anti-cancer drug combinations, validation of drug synergy in the in vivo setting and prioritization of combinations for...
9.
Moreno-Gonzalez A, Olson J, Klinghoffer R
Mol Cell Oncol
. 2016 Jun;
3(1):e1057315.
PMID: 27308571
Guided by the belief that the most important setting for understanding tumor response to drugs is the human patient, we developed a technology called CIVO. CIVO enables analysis of up...
10.
Kerwin W, Tretyak I, Grenley M, You S, Hatton B, Moreno-Gonzalez A, et al.
Magn Reson Med
. 2015 Sep;
76(3):946-52.
PMID: 26362018
Purpose: To facilitate decision making in the oncology clinic, technologies have recently been developed to independently inject and assess multiple anticancer agents directly in a patient's tumor. To increase the...